Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CFO Sandip Kapadia sold 354 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.83, for a total value of $20,825.82. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) traded up 6.365% during midday trading on Thursday, reaching $73.105. 2,653,929 shares of the company’s stock traded hands. The company’s market capitalization is $1.83 billion. The firm’s 50 day moving average price is $94.11 and its 200-day moving average price is $111.08. Intercept Pharmaceuticals, Inc. has a 1-year low of $54.98 and a 1-year high of $156.65.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The firm had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. During the same period last year, the business earned ($3.14) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% compared to the same quarter last year. Equities analysts expect that Intercept Pharmaceuticals, Inc. will post ($13.98) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/05/intercept-pharmaceuticals-inc-icpt-cfo-sandip-kapadia-sells-354-shares-of-stock.html.

A number of equities analysts have recently issued reports on ICPT shares. Cowen and Company reaffirmed an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. Wells Fargo & Company reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Jefferies Group LLC started coverage on Intercept Pharmaceuticals in a research report on Monday, July 10th. They set a “buy” rating and a $275.00 price target on the stock. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $332.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Intercept Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $162.88.

A number of hedge funds and other institutional investors have recently bought and sold shares of ICPT. US Bancorp DE acquired a new position in Intercept Pharmaceuticals in the first quarter valued at $130,000. Bank of New York Mellon Corp increased its stake in Intercept Pharmaceuticals by 10.2% in the first quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock valued at $7,725,000 after purchasing an additional 6,312 shares during the period. BNP Paribas Arbitrage SA increased its stake in Intercept Pharmaceuticals by 24.7% in the first quarter. BNP Paribas Arbitrage SA now owns 5,006 shares of the biopharmaceutical company’s stock valued at $566,000 after purchasing an additional 990 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 132 shares during the period. Finally, Swiss National Bank increased its stake in Intercept Pharmaceuticals by 2.2% in the first quarter. Swiss National Bank now owns 28,500 shares of the biopharmaceutical company’s stock valued at $3,223,000 after purchasing an additional 600 shares during the period. Institutional investors own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.